Etodolac - CAS 41340-25-4
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Cox-2 | COX
A non-selective inhibitor of COX
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
A non-selective inhibitor of COX
White solid
1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic Acid; (RS)-Etodolic Acid; (+/-)-Etodolac; AY 24236; Eccoxolac; Edolan; Etodine; Etodolic Acid; Etogesic; Lodin XL; Lodine; NIH 9918; NSC 282126; Napilac; Ramodar; Tedolan; Ultradol; Zedolac
100 mM in DMSO; 100 mM in ethanol
Please store the product under the recommended conditions in the Certificate of Analysis.
Quality Standard:
Melting Point:
Canonical SMILES:
1.Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.
Yang M1, Wang HT, Zhao M, Meng WB, Ou JQ, He JH, Zou B, Lei PG. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi: 10.1097/MD.0000000000001592.
Currently 2 difference classes of cyclooxygenase (COX)-2 inhibitors, coxibs and relatively selective COX-2 inhibitors, are available for patients requiring nonsteroidal anti-inflammatory drug (NSAID) therapy; their gastroprotective effect is hardly directly compared. The aim of this study was to compare the gastroprotective effect of relatively selective COX-2 inhibitors with coxibs. MEDLINE, EMBASE, and the Cochrane Library (from their inception to March 2015) were searched for potential eligible studies. We included randomized controlled trials comparing coxibs (celecoxib, etoricoxib, parecoxib, and lumiracoxib), relatively selective COX-2 inhibitors (nabumetone, meloxicam, and etodolac), and nonselective NSAIDs with a study duration ≥ 4 weeks. Comparative effectiveness and safety data were pooled by Bayesian network meta-analysis. The primary outcomes were ulcer complications and symptomatic ulcer. Summary effect-size was calculated as risk ratio (RR), together with the 95% confidence interval (CI).
2.An ionic liquid-in-water microemulsion as a potential carrier for topical delivery of poorly water soluble drug: Development, ex-vivo and in-vivo evaluation.
Goindi S1, Kaur R2, Kaur R2. Int J Pharm. 2015 Nov 30;495(2):913-23. doi: 10.1016/j.ijpharm.2015.09.066. Epub 2015 Oct 9.
In this paper, we report an ionic liquid-in-water (IL/w) microemulsion (ME) formulation which is able to solubilize etodolac (ETO), a poorly water soluble drug for topical delivery using BMIMPF6 (1-butyl-3-methylimidazolium hexafluorophosphate) as IL, Tween 80 as surfactant and ethanol as co-surfactant. The prepared ME was characterized for physicochemical parameters, subjected to ex-vivo permeation studies as well as in-vivo pharmacodynamic evaluation. The ex-vivo drug permeation studies through rat skin was performed using Franz-diffusion cell and the IL/w based ME showed maximum mean cumulative percent permeation of 99.030±0.921% in comparison to oil-in-water (o/w) ME (61.548±1.875%) and oily solution (48.830±2.488%) of ETO. In-vivo anti-arthritic and anti-inflammatory activities of the prepared formulations were evaluated using different rodent models and the results revealed that ETO loaded IL/w based ME was found to be more effective in controlling inflammation than oily solution, o/w ME and marketed formulation of ETO.
3.Selective COX-2 Inhibitors Significantly Reduce the Occurrence of Heterotopic Ossification After Hip Arthroscopic Surgery.
Rath E1, Warschawski Y1, Maman E1, Dolkart O1, Sharfman ZT1, Salai M1, Amar E2. Am J Sports Med. 2016 Mar;44(3):677-81. doi: 10.1177/0363546515618623. Epub 2015 Dec 22.
BACKGROUND: Heterotopic ossification (HO) after hip arthroscopic surgery is a common complication and may be associated with clinical sequelae such as pain, impingement, and decreased range of motion. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used medications for reducing or preventing HO.
4.Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics.
de Miranda Silva C1, Rocha A1, Tozatto E1, da Silva LM2, Donadi EA2, Lanchote VL3. J Pharm Biomed Anal. 2016 Feb 20;120:120-6. doi: 10.1016/j.jpba.2015.12.009. Epub 2015 Dec 12.
Etodolac is a non-steroidal anti-inflammatory drug with preferential inhibition of cyclooxigenase-2 and is widely used in the management of pain in patients with inflammatory arthritis. Etodolac is available as a racemic mixture of (-)-(R)-Etodolac and (+)-(S)-Etodolac; cyclooxigenases inhibition is attributed to (+)-(S)-Etodolac. According to our knowledge, this is the first method for determination of etodolac enantiomers in plasma using LC-MS/MS. Plasma extraction were performed with 25μL of plasma and 1mL of n-hexane:ethyl acetate (95:5); racemic ibuprofen was used as internal standard. Resolution of enantiomers were performed in a Chiralcel(®)OD-H column; deprotonated [M-H](-) and their respective ion products were monitored at transitions of 286>242 for etodolac enantiomers and 205>161 for ibuprofen. The quantitation limit was 3.2ng/mL for both enantiomers in plasma. The method was applied to study the pharmacokinetics of etodolac enantiomers after the administration of a 300 and 400mg dose of racemic drug to a healthy volunteer.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products

CAS 71125-38-7 Meloxicam

(CAS: 71125-38-7)

Meloxicam (Mobic) is a nonsteroidal anti-inflammatory agent with analgesic and fever reducer effects.

(CAS: 340267-36-9)

A potent, selective COX-2 inhibitor

CAS 189954-96-9 Firocoxib

(CAS: 189954-96-9)

A selective COX-2 inhibitor

CAS 168433-84-9 SC58451

(CAS: 168433-84-9)

SC58451 is a potent and selective Cox-2 (IC50= 1.1 nM) and was found to be orally active (EDs0 = 0.3 mpk) in the rat<br/>adjuvant-induced arthritis model with n...

CAS 123653-11-2 NS 398

NS 398
(CAS: 123653-11-2)

A selective COX-2 inhibitor

COX-2 Inhibitor I
(CAS: 416901-58-1)

An inhibitor of Cox-2

CAS 4394-00-7 Niflumic Acid

Niflumic Acid
(CAS: 4394-00-7)

A selective COX-2 inhibitor; GPR35 activator; Cox-2: IC50 = 918 nM (human); Cox-1: IC50 = 1.06 µM (human); GPR35: IC50 = 1.28 µM (human)

Indomethacin heptyl ester
(CAS: 282728-47-6)

A potent, non-selective COX-2 inhibitor

CAS 22161-81-5 (S)-Ketoprofen

(CAS: 22161-81-5)

A potent inhibitor of COX-1 and COX-2

CAS 141505-32-0 Ibuprofen lysinate

Ibuprofen lysinate
(CAS: 141505-32-0)

Dexibuprofen is a Cyclooxygenase inhibitor originated by Gebro Pharma GmbH. It is a non-steroidal anti-inflammatory drug as the active dextrorotatory enantiomer...

CAS 50-78-2 Aspirin

(CAS: 50-78-2)

A salicylate and irreversible COX1 and COX2 inhibitor

CAS 62-44-2 Phenacetin

(CAS: 62-44-2)

Phenacetin is a non-opioid analgesic without anti-inflammatory properties. It is a pain-relieving and fever-reducing drug and was withdrawn from the Canadian ma...

CAS 123653-11-2 NS 398

NS 398
(CAS: 123653-11-2)

A selective COX-2 inhibitor

CAS 41340-25-4 Etodolac

(CAS: 41340-25-4)

A non-selective inhibitor of COX

CAS 61-68-7 Mefenamic Acid

Mefenamic Acid
(CAS: 61-68-7)

A competitive inhibitor of COX-1 and COX-2

CAS 51146-56-6 (S)-(+)-Ibuprofen

(CAS: 51146-56-6)

Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activi...

CAS 170569-88-7 Mavacoxib

(CAS: 170569-88-7)

Mavacoxib, a pyrazol derivative, has been found to be a COX-2 Inhibitor that could be used in pain and inflammation therapy for dogs.

CAS 169590-42-5 Celecoxib

(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

CAS 15307-79-6 Diclofenac Sodium

Diclofenac Sodium
(CAS: 15307-79-6)

A non-selective COX inhibitor with IC50 of 0.5 μg/ml and 0.5 μg/ml for COX-1 and -2 in intact cells, respectively

CAS 13220-57-0 Tryptanthrin

(CAS: 13220-57-0)

A potent inhibitor of Cox-2, IDO and NOS II

Chemical Structure

CAS 41340-25-4 Etodolac

Quick Inquiry

Verification code

Featured Items